Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study is being carried out to evaluate the biological, technical and clinical/biological efficacy of this technique, the practice of which is standardized in the department, in order to evaluate our practices and to improve them if necessary. As part of this study, the investigators will ask all patients scheduled for this procedure to participate in this observational prospective study without changing usual practices.
The objective of the study is to conduct a prospective evaluation of the practice of apheresis by Double Filtration System Cascade system in a university centre in current practice with evaluation of the technical and biological effectiveness as the main objective and clinical and biological tolerance as the secondary objective for all consecutive sessions performed in a university centre over a period of 1 year.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Apheresis by DFPP and biological efficiency | quantification of the purification carried out (volume) | over a period of one year |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical side effects | catheter dysfunction | within 1 hour of all session |
| Biological side effects | Bleeding rate | within 1 hour of all session |
Not provided
Inclusion Criteria:
Over 18 years of age I indication for plasmapheresis and hospitalized at Chu de Nimes.
Exclusion Criteria:
Under guardianship or curatorship Refusal to participate
Not provided
Not provided
Not provided
All patients over 18 years of age who consecutively benefit from plasmapheresis sessions by double cascade filtration system during hospitalization at the University Hospital of Nîmes, within the framework of the usual indications retained in the department for a period of 12 months.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Olivier Moranne, MD, PhD | CHU Nîmes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nîmes, Hôpital Universitaire Caremeau | Nîmes | 30029 | France |
Not provided
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
| variation of Hb, platelet and albumin before and after session | % of Hb, platelet and albumin | within 1 hour of all session |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |